WO2023237930 - AMORPHOUS (A-POLYMORPHIC) PSILOCYBIN
National phase entry:
Publication Number
WO/2023/237930
Publication Date
14.12.2023
International Application No.
PCT/IB2023/000349
International Filing Date
08.06.2023
Title **
[English]
AMORPHOUS (A-POLYMORPHIC) PSILOCYBIN
[French]
PSILOCYBINE AMORPHE (A-POLYMORPHE)
Applicants **
DIAMOND THERAPEUTICS INC.
Inventors
BLUMSTOCK, Judith
BROWN, David, Roger
STEUP, Christian
ZEPLICHAL, Marc
Priority Data
63/350,828
09.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3638 | |
| EPO | Filing, Examination, Granting | 43047 | |
| Japan | Filing, Examination, Granting | 3544 | |
| South Korea | Filing, Examination, Granting | 5129 | |
| USA | Filing, Examination, Granting | 16940 |
Total:
72,298
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are compositions comprising amorphous psilocybin. The amorphous psilocybin may be a synthetic, a-polymorphic psilocybin. Also disclosed herein are methods of treatment using amorphous psilocybin and methods of manufacturing amorphous psilocybin.[French]
L'invention concerne des compositions comprenant de la psilocybine amorphe. La psilocybine amorphe peut être une psilocybine synthétique et polymorphe. L'invention concerne également des procédés de traitement à l'aide de psilocybine amorphe et des procédés de fabrication de psilocybine amorphe.